» Articles » PMID: 37185957

Mitochondria and the Eye-manifestations of Mitochondrial Diseases and Their Management

Overview
Journal Eye (Lond)
Specialty Ophthalmology
Date 2023 May 15
PMID 37185957
Authors
Affiliations
Soon will be listed here.
Abstract

Historically, distinct mitochondrial syndromes were recognised clinically by their ocular features. Due to their predilection for metabolically active tissue, mitochondrial diseases frequently involve the eye, resulting in a range of ophthalmic manifestations including progressive external ophthalmoplegia, retinopathy and optic neuropathy, as well as deficiencies of the retrochiasmal visual pathway. With the wider availability of genetic testing in clinical practice, it is now recognised that genotype-phenotype correlations in mitochondrial diseases can be imprecise: many classic syndromes can be associated with multiple genes and genetic variants, and the same genetic variant can have multiple clinical presentations, including subclinical ophthalmic manifestations in individuals who are otherwise asymptomatic. Previously considered rare diseases with no effective treatments, considerable progress has been made in our understanding of mitochondrial diseases with new therapies emerging, in particular, gene therapy for inherited optic neuropathies.

Citing Articles

A treatment within sight: challenges in the development of stem cell-derived photoreceptor therapies for retinal degenerative diseases.

Beaver D, Limnios I Front Transplant. 2024; 2:1130086.

PMID: 38993872 PMC: 11235385. DOI: 10.3389/frtra.2023.1130086.


Electrodiagnostic tests of the visual pathway and applications in neuro-ophthalmology.

Calcagni A, Neveu M, Jurkute N, Robson A Eye (Lond). 2024; 38(12):2392-2405.

PMID: 38862643 PMC: 11306601. DOI: 10.1038/s41433-024-03154-6.


Mother's Curse effects on lifespan and aging.

Edmands S Front Aging. 2024; 5:1361396.

PMID: 38523670 PMC: 10957651. DOI: 10.3389/fragi.2024.1361396.


Hereditary Optic Neuropathies: A Systematic Review on the Interplay between Biomaterials and Induced Pluripotent Stem Cells.

Ladero M, Reche-Sainz J, Gallardo M Bioengineering (Basel). 2024; 11(1).

PMID: 38247929 PMC: 10813088. DOI: 10.3390/bioengineering11010052.


Polycystic Ovary Syndrome and Oxidative Stress-From Bench to Bedside.

Zeber-Lubecka N, Ciebiera M, Hennig E Int J Mol Sci. 2023; 24(18).

PMID: 37762427 PMC: 10531631. DOI: 10.3390/ijms241814126.

References
1.
Sorkin J, Shoffner J, Grossniklaus H, Drack A, Lambert S . Strabismus and mitochondrial defects in chronic progressive external ophthalmoplegia. Am J Ophthalmol. 1997; 123(2):235-42. DOI: 10.1016/s0002-9394(14)71041-4. View

2.
Newman N, Yu-Wai-Man P, Biousse V, Carelli V . Understanding the molecular basis and pathogenesis of hereditary optic neuropathies: towards improved diagnosis and management. Lancet Neurol. 2022; 22(2):172-188. DOI: 10.1016/S1474-4422(22)00174-0. View

3.
Pearson H, Lobel J, Kocoshis S, NAIMAN J, WINDMILLER J, Lammi A . A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J Pediatr. 1979; 95(6):976-84. DOI: 10.1016/s0022-3476(79)80286-3. View

4.
Bucelli R, Lee M, McClelland C . Chronic Progressive External Ophthalmoplegia in the Absence of Ptosis. J Neuroophthalmol. 2016; 36(3):270-4. DOI: 10.1097/WNO.0000000000000384. View

5.
Del Dotto V, Carelli V . Dominant Optic Atrophy (DOA): Modeling the Kaleidoscopic Roles of OPA1 in Mitochondrial Homeostasis. Front Neurol. 2021; 12:681326. PMC: 8220150. DOI: 10.3389/fneur.2021.681326. View